Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
- ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform
- Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ
- ARS Pharmaceuticals Reports 2025 Results and neffy Growth